StockNews.com Initiates Coverage on Check-Cap (NASDAQ:CHEK)

Analysts at StockNews.com initiated coverage on shares of Check-Cap (NASDAQ:CHEK) in a research report issued on Sunday. The firm set a “sell” rating on the medical research company’s stock.

Check-Cap Stock Performance

Shares of CHEK opened at $1.53 on Friday. The firm has a market capitalization of $8.95 million, a price-to-earnings ratio of -0.51 and a beta of 0.17. The business’s fifty day moving average price is $0.99 and its two-hundred day moving average price is $1.48. Check-Cap has a 52 week low of $0.56 and a 52 week high of $3.45.

Check-Cap Company Profile

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation.